Nuvation Bio (NUVB) Income from Continuing Operations (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Income from Continuing Operations of 5397000.0 for Q1 2026, up 110.14% year-over-year from 2568313.76 in Q1 2025, and up 114.75% quarter-over-quarter from 36592000.0 in Q4 2025.
Powered by 
Analysis
Nuvation Bio (NUVB) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Income from Continuing Operations for 7 consecutive years, with 5397000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 110.14% year-over-year to 5397000.0; the TTM figure through Mar 2026 stood at 145994000.0 (up 75.92% YoY), while the FY2025 annual figure was 204627000.0, up 63.97% from the prior year.
- Income from Continuing Operations advanced to 5397000.0 in Q1 2026 per NUVB's latest filing, from 36592000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5397000.0 in Q1 2026 and bottomed at 462492000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 55715882.35 across 5 years, with a median of 27203000.0 in 2022.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 2140.76% — and 2026, when it jumped 110.14%.
- Nuvation Bio's Income from Continuing Operations stood at 20845000.0 in 2022, then jumped by 33.86% to 13787000.0 in 2023, then slumped by 258.63% to 49445000.0 in 2024, then gained by 25.99% to 36592000.0 in 2025, then surged by 114.75% to 5397000.0 in 2026.
- Business Quant data shows NUVB's Income from Continuing Operations at 5397000.0 in Q1 2026, 36592000.0 in Q4 2025, and 55792000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Nuvation Bio | 2.38 Bn | 2.38 Bn | 30.78 Mn | -62.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -62.84 Mn |
| Mar 31, 2026 | 5.40 Mn |
| Dec 31, 2025 | 5.10 Mn |
| Sep 30, 2025 | -55.79 Mn |
| Jun 30, 2025 | -59.01 Mn |
| Mar 31, 2025 | -53.24 Mn |
| Dec 31, 2024 | -49.45 Mn |
| Sep 30, 2024 | -41.21 Mn |
| Jun 30, 2024 | -462.49 Mn |
| Mar 31, 2024 | -14.79 Mn |
| Dec 31, 2023 | -13.79 Mn |
| Sep 30, 2023 | -19.65 Mn |
| Jun 30, 2023 | -20.64 Mn |
| Mar 31, 2023 | -21.73 Mn |
| Dec 31, 2022 | -20.85 Mn |
| Sep 30, 2022 | -27.20 Mn |
| Jun 30, 2022 | -34.86 Mn |
| Mar 31, 2022 | -21.29 Mn |
| Dec 31, 2021 | -25.13 Mn |
| Sep 30, 2021 | -21.98 Mn |